FDA Panel Targets Testosterone Therapy Risks
A U.S. Food and Drug Administration advisory panel on Wednesday urged the agency to direct testosterone therapy drug manufacturers to further assess the cardiovascular risks associated with their treatments and recommended...To view the full article, register now.
Already a subscriber? Click here to view full article